As more ADCs receive Accelerated Approval and Fast Track Designation, expediting the transition to the clinic becomes a strategic priority for developers. This underscores the...

With Nintedanib and Pirfenidone set to lose their patents in the next 3-6 years, Pliant Therapeutics moving into phase 2b, readouts expected from FibroGen's phase 3 trial and...